Liberate Medical develops a non-invasive respiratory muscle stimulator called VentFree for patients on mechanical ventilation. The device contracts expiratory muscles during mechanical ventilation to keep them active, potentially reducing atrophy and the duration of mechanical ventilation.

Liberate Medical

Liberate Medical is a medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders.

Liberate's lead product, the VentFree™ respiratory muscle stimulator. Invasive mechanical ventilation commonly weakens the breathing muscles, increasing the need for further ventilator support.  VentFree applies proprietary, non-invasive, electrical stimulation to the expiratory muscles in synchrony with exhalation while a patient is on mechanical ventilation. This breakthrough therapy, which is quick and simple to use, is intended to reduce abdominal muscle atrophy and the time taken to liberate patients from mechanical ventilation.  

Reduced days on mechanical ventilation can potentially lead to reduced morbidity and mortality, improved quality of life, and considerable savings for the health care provider. 

Keyhorse Capital (KSTC)

MedTech Innovator

National Science Foundation

The Vogt Awards

Newchip Accelerator

XLerateHealth

🚀 Exciting News from Liberate Medical! 🚀

We're thrilled to announce the launch of the PREVENT trial - a pivotal clinical trial that aims to demonstrate that our VentFree® Respiratory Muscle Stimulator reduces duration of invasive mechanical ventilation in patients at risk of being difficult to wean. 

🙏 Thank you and congratulations to everyone who has contributed to the successful launch of this important study. A special mention goes to The Prince of Wales Hospital, Baylor College of Medicine, and Providence Regional Medical Center Everett - Colby Campus who were the first sites to enroll patients worldwide! 

🌍 The PREVENT study aims to enroll 272 patients from up to 25 sites across the US, Australia and the EU and was made possible with a significant $6.5M grant from the US Department of Defense. 

🔗 Read the full press release here: https://lnkd.in/gMRYuwbK

Our co-founder and CEO, Angus M. was recently a guest on the Medsider podcast with host Scott Nelson 🎙️. Have a listen if you would like to learn more about our founding story, approach to product development and our upcoming pivotal trial.

Full details of the PREVENT study will be announced soon!

Metric
Company Name	Liberate Medical
Symbol
MSH ID	COM:LIBERATEMEDICAL
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage
Employee Count	13
Website	liberatemedical.com
LinkedIn	liberate-medical-llc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LIBERATEMEDICAL

Liberate Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue